T1	intervention 29 50	trastuzumab emtansine
T2	control 58 84	trastuzumab plus docetaxel
T3	total-participants 587 590	137
T4	eligibility 592 658	with HER2-positive MBC or recurrent locally advanced breast cancer
T5	control-participants 721 723	70
T6	intervention-participants 739 741	67
T9	outcome 1073 1083	Median PFS
T10	cv-cont-median 1088 1098	9.2 months
T11	iv-cont-median 1111 1122	14.2 months
T14	outcome 1178 1194	median follow-up
T15	iv-cont-median 1213 1222	14 months
T17	cv-bin-percent 1245 1250	58.0%
T18	iv-bin-percent 1288 1293	64.2%
T19	outcome 1353 1367	safety profile
T20	outcome 1390 1414	grade â‰¥ 3 adverse events
T21	iv-bin-percent 1421 1426	46.4%
T22	cv-bin-percent 1429 1434	90.9%
T23	outcome 1452 1478	treatment discontinuations
T24	iv-bin-percent 1480 1484	7.2%
T25	cv-bin-percent 1487 1492	34.8%
T26	outcome 1511 1522	serious AEs
T27	iv-bin-percent 1524 1529	20.3%
T28	cv-bin-percent 1532 1537	25.8%
T29	outcome 1552 1554	OS
T31	iv-cont-median 1635 1644	23 months
T8	outcome 1237 1240	ORR
T7	outcome-Measure 865 896	progression-free survival (PFS)
T12	outcome-Measure 901 907	safety
T13	outcome-Measure 943 964	overall survival (OS)
T16	outcome-Measure 966 995	objective response rate (ORR)
T30	outcome-Measure 997 1027	duration of objective response
T32	outcome-Measure 1029 1050	clinical benefit rate
T33	outcome-Measure 1056 1071	quality of life
